CytoDyn (CytoDyn) Dividend Payout Ratio : 0.00 (As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Dividend Payout Ratio?

CytoDyn's dividend payout ratio for the months ended in Feb. 2024 was 0.00.

The historical rank and industry rank for CytoDyn's Dividend Payout Ratio or its related term are showing as below:

CYDY's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-28), the Dividend Yield % of CytoDyn is 0.00%.

CytoDyn's Dividends per Share for the months ended in Feb. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

CytoDyn Dividend Payout Ratio Historical Data

The historical data trend for CytoDyn's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Dividend Payout Ratio Chart

CytoDyn Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Dividend Payout Ratio

Get a 7-Day Free Trial

CytoDyn Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CytoDyn's Dividend Payout Ratio

For the Biotechnology subindustry, CytoDyn's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's Dividend Payout Ratio falls into.

CytoDyn Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

CytoDyn's Dividend Payout Ratio for the fiscal year that ended in May. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: May. 2023 )	/	EPS without NRI (A: May. 2023 )
	=	0	/	-0.09
	=	N/A

CytoDyn's Dividend Payout Ratio for the quarter that ended in Feb. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Feb. 2024 )	/	EPS without NRI (Q: Feb. 2024 )
	=	0	/	-0.007
	=	N/A

CytoDyn (OTCPK:CYDY) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

CytoDyn Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of CytoDyn's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660